NO20021959L - Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer - Google Patents

Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer

Info

Publication number
NO20021959L
NO20021959L NO20021959A NO20021959A NO20021959L NO 20021959 L NO20021959 L NO 20021959L NO 20021959 A NO20021959 A NO 20021959A NO 20021959 A NO20021959 A NO 20021959A NO 20021959 L NO20021959 L NO 20021959L
Authority
NO
Norway
Prior art keywords
tetrahydrotiopyranephthalazinone
derivatives
pde4 inhibitors
pde4
inhibitors
Prior art date
Application number
NO20021959A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021959D0 (no
Inventor
Armin Hatzelmann
Daniela Bundschuh
Hans-Peter Kley
Geert Jan Sterk
Ivonne Johanna Van Der Laan
Hendrik Timmerman
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of NO20021959D0 publication Critical patent/NO20021959D0/no
Publication of NO20021959L publication Critical patent/NO20021959L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20021959A 1999-10-25 2002-04-25 Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer NO20021959L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121243 1999-10-25
US20395000P 2000-05-12 2000-05-12
PCT/EP2000/010445 WO2001030777A1 (en) 1999-10-25 2000-10-24 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Publications (2)

Publication Number Publication Date
NO20021959D0 NO20021959D0 (no) 2002-04-25
NO20021959L true NO20021959L (no) 2002-05-29

Family

ID=26153155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021959A NO20021959L (no) 1999-10-25 2002-04-25 Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer

Country Status (20)

Country Link
US (2) US6544993B1 (pl)
EP (1) EP1244654A1 (pl)
JP (1) JP2003512466A (pl)
KR (1) KR20020043238A (pl)
CN (1) CN1146562C (pl)
AU (1) AU781137B2 (pl)
BR (1) BR0014990A (pl)
CA (1) CA2388119A1 (pl)
CZ (1) CZ20021457A3 (pl)
EA (1) EA005856B1 (pl)
HK (1) HK1047276A1 (pl)
HR (1) HRP20020350A2 (pl)
HU (1) HUP0203487A2 (pl)
IL (1) IL148807A0 (pl)
MX (1) MXPA02003581A (pl)
NO (1) NO20021959L (pl)
PL (1) PL354979A1 (pl)
SK (1) SK7232002A3 (pl)
TR (1) TR200201128T2 (pl)
WO (1) WO2001030777A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005856B1 (ru) * 1999-10-25 2005-06-30 Алтана Фарма Аг Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
MXPA03007310A (es) * 2001-02-15 2003-12-04 Altana Pharma Ag Derivados de ftalazinona piperidino como inhibidores pde4.
CN1503792A (zh) 2001-04-25 2004-06-09 ��̹��ҽҩ��˾ 新的酞嗪酮
EA200301101A1 (ru) 2001-04-25 2004-04-29 Алтана Фарма Аг Производные пиперазина и их применение в качестве ингибиторов pde4
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2004018450A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
CA2494650A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
ES2286491T3 (es) 2002-08-10 2007-12-01 Nycomed Gmbh Piperidina-ftalazonas sustituidas con pirrolidinadiona, como agentes inhibidores de la pde4.
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
WO2004062671A2 (en) * 2003-01-14 2004-07-29 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
CA2554797C (en) 2004-02-04 2012-09-04 Altana Pharma Ag 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
DK2589599T3 (da) * 2004-03-03 2014-10-06 Takeda Gmbh Hidtil ukendte hydroxy-6-heteroarylphenanthridiner og deres anvendelse som PDE4-inhibitorer
ES2617339T3 (es) * 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
DE69332762T2 (de) 1992-12-02 2003-08-14 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
JP2001508078A (ja) 1997-01-15 2001-06-19 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノン
AU1760399A (en) 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
SI1042319T1 (en) * 1997-12-15 2004-08-31 Altana Pharma Ag Dihydrobenzofurans
WO1999047505A1 (en) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
EA005856B1 (ru) * 1999-10-25 2005-06-30 Алтана Фарма Аг Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4

Also Published As

Publication number Publication date
EP1244654A1 (en) 2002-10-02
WO2001030777A1 (en) 2001-05-03
HK1047276A1 (zh) 2003-02-14
CZ20021457A3 (cs) 2002-07-17
KR20020043238A (ko) 2002-06-08
PL354979A1 (pl) 2004-03-22
IL148807A0 (en) 2002-09-12
AU781137B2 (en) 2005-05-05
BR0014990A (pt) 2002-06-18
SK7232002A3 (en) 2002-09-10
US6544993B1 (en) 2003-04-08
CA2388119A1 (en) 2001-05-03
AU1515101A (en) 2001-05-08
MXPA02003581A (es) 2002-10-23
US20030166655A1 (en) 2003-09-04
HUP0203487A2 (hu) 2003-02-28
TR200201128T2 (tr) 2002-08-21
CN1382137A (zh) 2002-11-27
JP2003512466A (ja) 2003-04-02
NO20021959D0 (no) 2002-04-25
US6846821B2 (en) 2005-01-25
EA200200381A1 (ru) 2002-10-31
HRP20020350A2 (en) 2004-02-29
EA005856B1 (ru) 2005-06-30
CN1146562C (zh) 2004-04-21

Similar Documents

Publication Publication Date Title
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20014642L (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
DE60002193D1 (de) Metalloprotease inhibitoren
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20025811D0 (no) Forbindelser som er effektive som beta-2-adrenoreseptor- anonister så vel som PDE4-inhibitorer
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20021407D0 (no) Bifenylderivater anvendt som NHE-3-inhibitorer
DK1183251T3 (da) Indolylpiperidinderivater som antihistamin- og antiallergimidler
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20014243D0 (no) Dihetero-substituerte metalloprotease inhibitorer
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
NO20020592D0 (no) Fluorenderivater som integrininhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application